Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcos de Lima

Showing results (181-190 of 321) with videos related to

Pageof 33
Sort By:
American Journal of Hematology|April 21, 2020
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction modelsGouri Dharmavaram, Shufen Cao, Suchitra Sundaram, et al.
Cells|July 29, 2023
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T CellsKe Zeng, Meixian Huang, Mi-Ae Lyu, et al.
American Journal of Hematology|April 23, 2009
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphomaChitra Hosing, Rima M Saliba, Sheena Ahlawat, et al.
Advances in Hematology|November 24, 2011
Steroid-Refractory Acute GVHD: Predictors and OutcomesJason R Westin, Rima M Saliba, Marcos De Lima, et al.
Blood|April 8, 2004
Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel, Rima Saliba, Krystal Hicks, et al.
Blood Advances|November 3, 2018
Aberrant GSK3β nuclear localization promotes AML growth and drug resistanceJames J Ignatz-Hoover, Victoria Wang, Nathan M Mackowski, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
The American Journal of Cardiology|November 20, 2020
Socio-Economic Burden of Myocardial Infarction Among Cancer PatientsAvirup Guha, Amit Kumar Dey, Sadeer Al-Kindi, et al.
Clinical Lymphoma & Myeloma|September 26, 2009
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib eraRichard Champlin, Marcos de Lima, Partow Kebriaei, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk PatientsPaolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
Pageof 33

Showing results (181-190 of 321) with videos related to

Sort By:
Pageof 33
American Journal of Hematology|April 21, 2020
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction modelsGouri Dharmavaram, Shufen Cao, Suchitra Sundaram, et al.
Cells|July 29, 2023
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T CellsKe Zeng, Meixian Huang, Mi-Ae Lyu, et al.
American Journal of Hematology|April 23, 2009
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphomaChitra Hosing, Rima M Saliba, Sheena Ahlawat, et al.
Advances in Hematology|November 24, 2011
Steroid-Refractory Acute GVHD: Predictors and OutcomesJason R Westin, Rima M Saliba, Marcos De Lima, et al.
Blood|April 8, 2004
Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel, Rima Saliba, Krystal Hicks, et al.
Blood Advances|November 3, 2018
Aberrant GSK3β nuclear localization promotes AML growth and drug resistanceJames J Ignatz-Hoover, Victoria Wang, Nathan M Mackowski, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
The American Journal of Cardiology|November 20, 2020
Socio-Economic Burden of Myocardial Infarction Among Cancer PatientsAvirup Guha, Amit Kumar Dey, Sadeer Al-Kindi, et al.
Clinical Lymphoma & Myeloma|September 26, 2009
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib eraRichard Champlin, Marcos de Lima, Partow Kebriaei, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk PatientsPaolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
Pageof 33